Related Experiment Video
Updated: May 16, 2026
09:21
Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons
Published on: July 7, 2023
Nature-origin phthalides for Parkinson's disease drug development
Jayaraman Vinayagam1, D Kalaivani2, G P Senthilkumar3
1Department of Chemistry, Greensmed Labs, Chennai, Tamil Nadu, 600097, India.
Neurochemistry International
|May 14, 2026
Summary
Natural phthalide compounds show multi-target neuroprotective effects against Parkinson's disease (PD) progression. These compounds offer a promising avenue for novel, disease-modifying treatments by targeting oxidative stress, inflammation, and α-synuclein accumulation.
Area of Science:
- Neuroscience
- Pharmacology
- Natural Product Chemistry
Background:
- Parkinson's disease (PD) involves neurodegeneration, α-synuclein buildup, and oxidative stress, with current treatments only managing symptoms.
- Existing PD therapies lack disease-modifying or neuroprotective capabilities to halt neurodegeneration.
- There is a critical need for novel agents that can offer multi-target neuroprotection to combat PD progression.
Purpose of the Study:
- To review the potential of naturally occurring phthalide compounds as multi-target neuroprotective agents for Parkinson's disease.
- To discuss the etiology, pathogenesis, and current treatment limitations of PD.
- To explore the relevance of specific phthalides (e.g., DL-3-n-butylphthalide, ligustilide) in preclinical models of PD.
Main Methods:
- Literature review of studies on Parkinson's disease pathogenesis and treatment.
- Analysis of in vitro and animal studies investigating the neuroprotective effects of phthalide derivatives.
- Examination of the molecular mechanisms underlying phthalide activity, including anti-oxidative, anti-inflammatory, and anti-α-synuclein properties.
Main Results:
- Phthalides, derived from medicinal plants like Ligusticum chuanxiong and Angelica sinensis, demonstrate significant neuroprotective potential.
- These compounds exhibit multi-target activities, including anti-oxidative, anti-inflammatory, anti-ferroptosis, anti-α-synuclein aggregation, and anti-monoamine oxidase B (MAO-B) effects.
- Preclinical studies indicate that phthalides can mitigate key pathological features of Parkinson's disease.
Conclusions:
- Naturally occurring phthalides represent a promising class of compounds for developing novel, disease-modifying therapies for Parkinson's disease.
- Their multi-target neuroprotective profile makes them attractive candidates for addressing the complex pathogenesis of PD.
- Further research into phthalides could lead to more effective treatments that prevent neurodegeneration in Parkinson's patients.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:21EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...